Tachycardia, Paroxysmal

• 

  Subject Areas on Research

  • Arrhythmogenic epilepsy: an hypothesis. 
  • Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. 
  • Clinical behavior of paroxysmal atrial tachycardia. 
  • Designing clinical trials for paroxysmal atrial tachycardia and other paroxysmal arrhythmias. 
  • Effect of dofetilide on survival in patients with supraventricular arrhythmias. 
  • Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. 
  • Elective prolongation of atrioventricular conduction by multiple discrete cryolesions: a new technique for the treatment of paroxysmal supraventricular tachycardia. 
  • Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group. 
  • Healthcare Resource Use and Expenditures in Patients Newly Diagnosed With Paroxysmal Supraventricular Tachycardia. 
  • Heart rate during spontaneous and induced paroxysmal supraventricular tachycardia. 
  • Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. 
  • Is it safe to use intravenous verapamil to treat a patient who is taking oral verapamil? 
  • Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia. 
  • Observations on the occurrence of atrial fibrillation in paroxysmal supraventricular tachycardia. 
  • Persistent repetitive supraventricular tachycardia. 
  • Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. 
  • Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. 
  • Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. 
  • Rates and predictors of hospital and emergency department care after catheter ablation of atrial fibrillation. 
  • Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia in untreated patients. 
  • Supraventricular tachycardia dependent upon accessory pathways in the absence of ventricular preexcitation. 
  • Surgical treatment of supraventricular tachyarrhythmias. 
  • Sympathectomy in the treatment of angina and arrhythmias. 
  • Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. 
  • The spontaneous occurrence of paroxysmal supraventricular tachycardia. 
  • Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States.